This content is machine translated Multiple sclerosis Spirulina as adjuvant therapy? Reduction of cytokines and inflammation Disease-modifying therapies reduce relapse rates in multiple sclerosis. However, they often only incompletely address the aspects of oxidative stress and long-term neurodegeneration. Spirulina, a microalgae, is known for its strong...…
View Post 12 min This content is machine translated HER2-positive breast cancer ENPP1 as a biomarker for poor prognosis and early detection of brain metastases Around 15-20% of all breast cancer cases are HER2-positive, which is a subtype with an aggressive course and an increased tendency to metastasize to the brain. A new study now...…
View Post 6 min This content is machine translated Chronic insomnia in adults: Guideline recommendations CBT-i as first choice – pharmacotherapy as secondary intervention Sleep disorders are often associated with pronounced daytime sleepiness, difficulty concentrating and increased feelings of stress. Diagnosis is generally based on the clinical history; if necessary, an actigraphy or polysomnigraphy...…
View Post 5 min This content is machine translated Multiple sclerosis Multiple sclerosis 2025: New strategies against progression and the role of microglia The treatment of multiple sclerosis has made enormous progress thanks to highly effective disease-modifying therapies, in particular anti-CD20 antibodies. For most newly diagnosed patients, a life without disability is realistic....…
View Post 4 min RX Education Geriatrics Neurology Pharmacology and toxicology Studies Opicapon: double benefit for motor function and sleep in Parkinson’s disease Sleep disorders are among the most common non-motor Parkinson’s symptoms. The targeted treatment of sleep disorders is an important part of Parkinson’s therapy and can significantly improve quality of life....…
View Post 5 min This content is machine translated Multiple sclerosis Avoiding the nocebo trap with natalizumab biosimilars Monoclonal antibodies such as natalizumab are indispensable for multiple sclerosis therapy. A first recently approved biosimilar is clinically equivalent, as studies have shown. Nevertheless, reservations are widespread in practice. Patients...…
View Post 5 min This content is machine translated Brain health News from the Swiss Brain Health Plan (SBHP) 2023-2033 The high burden of neurological and psychiatric diseases makes a national strategy and close interdisciplinary collaboration essential. The Swiss Brain Health Plan (SBHP) 2023-2033, a comprehensive initiative to promote brain...…
View Post 3 min This content is machine translated Friedreich's ataxia Treatment options have improved Friedreich’s ataxia is a hereditary neurodegenerative disease that is classically characterized by uncoordinated movements, postural and gait disorders, as well as balance and visual disorders. Subgroups of those affected also...…
View Post 16 min This content is machine translated Low-grade pediatric gliomas Consideration of the tumor microenvironment opens up new treatment options Low-grade gliomas are among the most common primary brain tumors in childhood and can affect patients for life, which is why early diagnosis involving the tumor microenvironment is of significant...… CME-Test
View Post 6 min This content is machine translated DOAK optimization, ABC pathway and lessons learned from the FXI/XIa pipeline Stroke prevention for atrial fibrillation 2025 Atrial fibrillation is the most important treatable risk factor for ischemic strokes in 2025 – and at the same time an area where precision makes all the difference. The major...…
View Post 8 min This content is machine translated New perspectives for clinics and research Ageing, cellular senescence and Parkinson’s disease Parkinson’s is one of the most common neurodegenerative diseases and continues to pose major challenges for neurology. It has long been clear that age is the decisive risk factor –...…
